Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Never needed the full 12mg dose to see results
In obesity trials, patients receiving semaglutide lost significantly more weight than placebo groups
2 way Dual Activation GHRH-R (CJC-1295) + GHS-R1a (Ipamorelin) two complementary pituitary targets 2-4x GH AUC Demonstrated Synergy Area under the GH curve 2 to 4 times greater than each peptide in monotherapy 5.8 - 8.1 days CJC-1295 Half-Life Sustained elevation of IGF-1 for 9 to 11 days after a single injection 10 mg Pre-formulated mix 5 mg CJC-1295 (No DAC) + 5 mg Ipamorelin per vial | Purity 99% HPLC Selective Hormonal Profile Ipamorelin: no increase in cortisol, prolactin or ACTH (Raun et al., 1998) Mechanism of Action Dual-Channel Synergy Simultaneous activation of GHRH-R and GHS-R1a for amplified GH stimulation GHRH Lane CJC-1295 GHRH Analog (Mod GRF 1-29) A synthetic peptide of 29 amino acids that selectively binds to the GHRH receptor on pituitary somatotroph cells
Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study
US$ 23.51
US$ 25.24
US$ 29.96
US$ 25.22
